Gilead quarterly revenue rises 26% on remdesivir sales

Reuters · 02/04/2021 21:05
Gilead quarterly revenue rises 26% on remdesivir sales

- Gilead Sciences Inc GILD.O posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.

Remdesivir brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts' estimates of $1.34 billion, according to Refinitiv IBES data.


(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D'Silva)

((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;))